prof. dr. Anje Cauwels

Conference Paper
C3
open access

Teaching an old dog new tricks : activity-on-target interferon to treat T-cell acute lymphoblastic leukemia

Steven Goossens (UGent) , Anje Cauwels (UGent) , Tim Pieters (UGent) , Willem Daneels (UGent) , Pieter Van Vlierberghe (UGent) and Jan Tavernier (UGent)

(2020) EHA25 Virtual - The European Hematology Association, Abstracts.

Add to list

Journal Article
A1
open access

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Leander Huyghe (UGent) , Alexander Van Parys (UGent) , Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Stijn De Munter (UGent) , Jennyfer Bultinck (UGent) , Lennart Zabeau (UGent) , Jeroen Hostens, An Goethals, Nele Vanderroost (UGent) , et al.

(2020) EMBO MOLECULAR MEDICINE. 12(2).

Add to list

Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Dominiek Catteeuw (UGent) , Shengru Pang, Franciane Paul, Elke Rogge (UGent) , Annick Verhee (UGent) , Marco Prinz, Niko Kley, Gilles Uzé, et al.

(2019) JOURNAL OF AUTOIMMUNITY. 97. p.70-76

Add to list

IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

Bram Van Den Eeckhout (UGent) , Elianne Burg (UGent) , Anje Cauwels (UGent) , Frank Peelman (UGent) , Sandra Van Lint (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2018) Dendritic Cells, 15th International symposium, Abstracts.

Add to list

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Franciane Paul, Genevieve Garcin, Stefaan De Koker (UGent) , Alexander Van Parys (UGent) , Thomas Wüest (UGent) , Sarah Gerlo (UGent) , José Van Der Heyden (UGent) , Yan Bordat, et al.

(2018) CANCER RESEARCH. 78(2). p.463-474

Add to list

IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

Bram Van Den Eeckhout (UGent) , Elianne Burg (UGent) , Anje Cauwels (UGent) , Frank Peelman (UGent) , Sandra Van Lint (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2017) Defence is the best attack : immuno-oncology breakthroughs, EACR conference, Abstracts.

Add to list

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Geneviève Garcin, Jennyfer Bultinck (UGent) , Franciane Paul, Sarah Gerlo (UGent) , José Van Der Heyden (UGent) , Yann Bordat, Dominiek Catteeuw (UGent) , Lode De Cauwer (UGent) , et al.

(2017) ONCOIMMUNOLOGY. 7(3).

Add to list

Journal Article
A1
open access

Citrulline supplementation improves organ perfusion and arginine availability under conditions with enhanced arginase activity

Karolina AP Wijnands, Dennis M Meesters, Kevin WY van Barneveld, Ruben GJ Visschers, Jacob J Briedé, Benjamin Vandendriessche (UGent) , Hans MH van Eijk, Babs AFM Bessems, Nadine van den Hoven, Christian JH von Wintersdorff, et al.

(2015) NUTRIENTS. 7(7). p.5217-5238

Add to list

Journal Article
A1
open access

Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice

Robrecht Thoonen (UGent) , Anje Cauwels (UGent) , Kelly Decaluwé (UGent) , Sandra Geschka, Robert E Tainsh, Joris Delanghe (UGent) , Tino Hochepied (UGent) , Lode De Cauwer (UGent) , Elke Rogge (UGent) , Sofie Voet (UGent) , et al.

(2015) NATURE COMMUNICATIONS. 6.

Add to list

Journal Article
A2
open access

MAPK-activated protein kinase 2-deficiency causes hyperacute tumor necrosis factor-induced inflammatory shock

Benjamin Vandendriessche (UGent) , An Goethals, Alba Simats, Evelien Van Hamme (UGent) , Peter Brouckaert (UGent) and Anje Cauwels (UGent)

(2014) BMC PHYSIOLOGY. 14.

Academic Bibliography

prof. dr. Anje Cauwels

Teaching an old dog new tricks : activity-on-target interferon to treat T-cell acute lymphoblastic leukemia

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice

IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

IL-1β AcTaleukins : towards potent yet safe adjuvants for tumor vaccination

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Citrulline supplementation improves organ perfusion and arginine availability under conditions with enhanced arginase activity

Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice

MAPK-activated protein kinase 2-deficiency causes hyperacute tumor necrosis factor-induced inflammatory shock

Contents

Support

Contact